We are live on ! Find out more
YMAB

Y-mAbs Therapeutics
YMAB

Delisted

YMAB was delisted on the 15th of September, 2025.

Back to rankings

85 hedge funds and large institutions have $95.4M invested in Y-mAbs Therapeutics in 2023 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 32 increasing their positions, 27 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,400% more call options, than puts

Call options by funds: $50K | Put options by funds: $2K

19% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 27

2% more capital invested

Capital invested by funds: $93.6M → $95.4M (+$1.81M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.73% less ownership

Funds ownership: 44.21% → 43.48% (-0.73%)

7% less funds holding

Funds holding: 91 → 85 (-6)

32% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 19

Holders
85
Holders Change
-6
Holders Change %
-6.59%
% of All Funds
1.35%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
13
Increased
32
Reduced
27
Closed
19
Calls
$50K
Puts
$2K
Net Calls
+$48K
Net Calls Change
-$44K

Top Buyers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
+$1.75M
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$1.32M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.32M
4
N
Nuveen
North Carolina
+$936K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$821K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$2.67M
2
Millennium Management
Millennium Management
New York
-$2.06M
3
AG
Artal Group
Luxembourg
-$1.95M
4
E
Ergoteles
New York
-$936K
5
BlackRock
BlackRock
New York
-$889K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$11.8M -$889K -217,683 -8%
Vanguard Group
2
Vanguard Group
Pennsylvania
$11.4M +$92.9K +22,748 +1%
SI
3
Sofinnova Investments
California
$11M – – –
PCH
4
Polar Capital Holdings
United Kingdom
$9.98M – – –
D.E. Shaw & Co
5
D.E. Shaw & Co
New York
$3.96M +$1.32M +322,292 +69%
State Street
6
State Street
Massachusetts
$3.82M -$283K -69,321 -8%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$3.32M +$128K +31,351 +5%
Millennium Management
8
Millennium Management
New York
$3.12M -$2.06M -505,611 -45%
AQR Capital Management
9
AQR Capital Management
Connecticut
$2.4M -$3.58K -877 -0.2%
ACM
10
AIGH Capital Management
Maryland
$2.15M +$1.75M +428,412 New
Acadian Asset Management
11
Acadian Asset Management
Massachusetts
$2M +$821K +201,022 +101%
Point72 Asset Management
12
Point72 Asset Management
Connecticut
$1.79M -$377K -92,212 -21%
N
13
Nuveen
North Carolina
$1.67M +$936K +229,329 +220%
Jacobs Levy Equity Management
14
Jacobs Levy Equity Management
New Jersey
$1.62M +$1.32M +323,897 New
Citadel Advisors
15
Citadel Advisors
Florida
$1.53M -$2.67M -654,711 -68%
Northern Trust
16
Northern Trust
Illinois
$1.51M -$73.8K -18,082 -6%
Morgan Stanley
17
Morgan Stanley
New York
$1.25M -$178K -43,514 -15%
Charles Schwab
18
Charles Schwab
California
$1.18M -$65K -15,919 -6%
Two Sigma Advisers
19
Two Sigma Advisers
New York
$1.05M +$584K +143,100 +216%
JP Morgan Chase
20
JP Morgan Chase
New York
$979K +$665K +162,752 +498%
MSKCC
21
Memorial Sloan Kettering Cancer Center
New York
$958K – – –
Goldman Sachs
22
Goldman Sachs
New York
$956K -$515K -126,061 -40%
Connor, Clark & Lunn Investment Management (CC&L)
23
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$872K +$13K +3,194 +2%
XT
24
XTX Topco
Cayman Islands
$818K +$509K +124,703 +323%
GCP
25
GSA Capital Partners
United Kingdom
$809K +$255K +62,349 +63%
1
2 3 4 5

YMAB Hedge Fund Activity: Q1 2023 in Review

85 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q1 2023, worth a combined $95.4M — up 1.9% from $93.6M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of YMAB and 13 opened new positions — a net loss of 6 holders — while 27 trimmed existing stakes and 32 added.

The largest buyer was AIGH Capital Management, opening a new position worth an estimated $1.75M. The largest seller was Citadel Advisors, cutting an estimated $2.67M.

  • 85 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q1 2023, down from 91 in Q4 2022.
  • Funds reported $95.4M of Y-mAbs Therapeutics stock for Q1 2023, up 1.9% quarter-over-quarter.
  • 13 funds opened new Y-mAbs Therapeutics positions in Q1 2023 and 19 closed out, a net change of -6 holders.
  • The largest Y-mAbs Therapeutics buyer in Q1 2023 was AIGH Capital Management, an estimated $1.75M added.
  • The largest Y-mAbs Therapeutics seller in Q1 2023 was Citadel Advisors, an estimated $2.67M sold.

Based on aggregated 13F filings for Q1 2023.